VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PASGPassage Bio, Inc.
$5.59$18M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPASGEarnings History

PASG logoPassage Bio, Inc. (PASG) Earnings History

Net Loss

8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$38M
● Net Loss
TTM EPS (Diluted)
$-11.75
Per share, diluted
YoY EPS Growth
+33.1%
Excellent
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-113.8%
Return on Assets-55.3%
Record Annual Net Income-$13MFY2018
Record Quarterly EPS$-2.36Q1 2026
Consecutive Profitable Years0years
Q1 2026
Net Income-$8M
EPS (Diluted)$-2.36
YoY Growth+33.1%Excellent
QoQ Growth+41.8%Excellent

Loading earnings history...

Passage Bio, Inc. (PASG) Earnings Overview

As of June 19, 2026, Passage Bio, Inc. (PASG) reported trailing twelve-month net income of -$38M, reflecting +33.1% year-over-year growth. The company earned $-11.75 per diluted share over the past four quarters.

Looking at the long-term picture, PASG's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2018.

Passage Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including KRYS ($225M net income, 52.6% margin), RCKT (-$209M net income), RARE (-$609M net income, -85.4% margin), PASG has comparable earnings metrics. Compare PASG vs KRYS →

PASG Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
PASG logoPASGCurrent
-$38M$-11.75--113.8%+33.1%—
KRYS logoKRYS
$225M$7.3852.6%18.9%+128.0%
RCKT logoRCKT
-$209M$-1.87--60.3%+26.4%
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
FOLD logoFOLD
-$27M$-0.09-4.3%-11.6%+51.2%
ACAD logoACAD
$376M$2.1836.5%39.9%+68.4%
Best in group
Lowest in group

PASG Historical Earnings Data (2018–2025)

8 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$46M+29.7%-$43M$-14.35--
2024-$65M+36.5%-$70M$-21.44--
2023-$102M+25.0%-$100M$-37.29--
2022-$136M+26.6%-$138M$-50.00--
2021-$185M-65.2%-$186M$-69.51--
2020-$112M-145.9%-$113M$-57.80--
2019-$46M-257.4%-$37M$-45.60--
2018-$13M--$13M$-10.60--

Download Data

Export PASG earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

8+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PASG — Frequently Asked Questions

Quick answers to the most common questions about buying PASG stock.

What is PASG earnings per share (EPS)?

PASG trailing twelve-month (TTM) diluted EPS is $-11.75, reflecting +33.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.

What is Passage Bio, Inc.'s net income?

Passage Bio, Inc. (PASG) trailing twelve-month net income is $-38M as of 2025. Earnings grew +33.1% year-over-year.

Is PASG profitable?

PASG is not currently profitable on a TTM basis, reporting a net loss of $-38M. Net margin is N/A. Investors should monitor for a return to profitability.

What is PASG's earnings growth rate?

PASG compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.

What are PASG's profit margins?

Passage Bio, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -113.8%.

Is PASG growing earnings?

Yes, PASG earnings are accelerating — EPS growth of +33.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-38M. Earnings momentum is strengthening.

What was PASG's best earnings year?

Passage Bio, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.

What were PASG's earnings last quarter?

PASG's most recent reported quarter was Q1 2026. Net income was $-8M with diluted EPS of $-2.36. For a full breakdown of all quarters, see the quarterly earnings table on this page.

PASG Earnings Over Time (2018–2025)

Net income & EPS — annual and quarterly view